Cediranib

Cediranib

File:AZD2171.svg
Systematic (IUPAC) name
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Clinical data
Routes of administration	Oral
Pharmacokinetic data
Biological half-life	12 to 35 hours
Identifiers
ATC code	none
Chemical data
Formula	C25H27FN4O3
Molar mass	450.505 g/mol[[]]
(verify)

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.

On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

On 8th March 2010, AstraZeneca issued a press-release stating that Recentin had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader Avastin.

References

http://www.astrazeneca.com/media/latest-press-releases/2010-new/recoentin-horizon?itemId=8748245

External links

• AZD2171—AstraZeneca Pipeline